Synova Life Sciences

Synova Life Sciences is a private, pre-revenue medical device company that has developed the FDA 510(k)-cleared Synova WAVE system for rapid, high-viability adipocyte (fat cell) processing. The technology differentiates itself through a 3-minute processing time and superior cell viability (over 90%) compared to competitors, targeting the growing market for fat grafting and cell-based therapies in oncology and reconstructive surgery. Led by a founder-inventor CEO and an experienced operational and commercial team, the company is positioned to commercialize its platform for clinical use, though it faces risks related to market adoption, reimbursement, and competition from established players.

The Synova WAVE is an FDA 510(k)-cleared, closed-system medical device for the rapid (3-minute) processing of adipose tissue. It isolates adipocytes with high and consistent viability (>90%), as measured by metabolic activity staining, for use in autologous fat grafting and cell therapy applications.

Synova operates in the competitive medical device market for fat processing. It directly compares its WAVE system to a 'leading competitor,' claiming superior viability and consistency. It faces competition from other FDA-cleared automated systems as well as manual processing techniques, requiring it to demonstrate clear clinical and economic value to drive surgeon adoption.